"CTLA-4 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
| Descriptor ID |
D060908
|
| MeSH Number(s) |
D12.776.543.750.705.222.750 D23.050.301.264.894.158 D23.101.100.894.158
|
| Concept/Terms |
CTLA-4 Antigen- CTLA-4 Antigen
- Antigen, CTLA-4
- CTLA 4 Antigen
- Antigens, CD152
- CD152 Antigens
- Cytotoxic T-Lymphocyte-Associated Antigen 4
- Cytotoxic T Lymphocyte Associated Antigen 4
- Cytotoxic T-Lymphocyte Antigen 4
- Cytotoxic T Lymphocyte Antigen 4
- CD152 Antigen
- Antigen, CD152
|
Below are MeSH descriptors whose meaning is more general than "CTLA-4 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- CTLA-4 Antigen [D12.776.543.750.705.222.750]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CTLA-4 Antigen [D23.050.301.264.894.158]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CTLA-4 Antigen [D23.101.100.894.158]
Below are MeSH descriptors whose meaning is more specific than "CTLA-4 Antigen".
This graph shows the total number of publications written about "CTLA-4 Antigen" by people in this website by year, and whether "CTLA-4 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 10 | 24 | 34 |
| 2018 | 16 | 16 | 32 |
| 2019 | 4 | 10 | 14 |
| 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "CTLA-4 Antigen" by people in Profiles.
-
Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept. Eur J Gastroenterol Hepatol. 2021 12 01; 33(1S Suppl 1):e1051-e1056.
-
Favorable Outcome of COVID-19 Infection in a Pediatric Cancer Patient Receiving an Anti-PD-L1/Anti-CTLA-4 Combination. J Pediatr Hematol Oncol. 2021 10 01; 43(7):e1045-e1046.
-
SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis. Life Sci. 2021 Apr 01; 270:119124.
-
Immune Checkpoint Inhibitors-Related Cardiotoxicity. Am J Ther. 2020 Nov/Dec; 27(6):e591-e598.
-
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. J Immunother Cancer. 2020 10; 8(2).
-
Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey. J Immunother Cancer. 2020 10; 8(2).
-
Association of immune checkpoint inhibitors with respiratory infections: A review. Cancer Treat Rev. 2020 Nov; 90:102109.
-
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment. J Immunother Cancer. 2020 07; 8(2).
-
Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic. Lung Cancer. 2020 08; 146:376-377.
-
Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome? Br J Cancer. 2020 09; 123(5):691-693.